Evaluation of factors influencing adherence to treatment with sodium-glucose cotransporter type 2 inhibitor
Despite the emergence of new groups of drugs for the treatment of type 2 diabetes mellitus (DM2), the issue of optimal adherence to treatment remains of interest.The aim of this study was to investigate the factors that influence the adherence to treatment with sodium glucose co-transporter type 2 i...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Siberian State Medical University (Tomsk)
2020-10-01
|
| Series: | Бюллетень сибирской медицины |
| Subjects: | |
| Online Access: | https://bulletin.ssmu.ru/jour/article/view/2978 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849241367663869952 |
|---|---|
| author | D. A. Lebedev A. A. Mosikian A. Yu. Babenko |
| author_facet | D. A. Lebedev A. A. Mosikian A. Yu. Babenko |
| author_sort | D. A. Lebedev |
| collection | DOAJ |
| description | Despite the emergence of new groups of drugs for the treatment of type 2 diabetes mellitus (DM2), the issue of optimal adherence to treatment remains of interest.The aim of this study was to investigate the factors that influence the adherence to treatment with sodium glucose co-transporter type 2 inhibitor, empagliflozin (Jardiance, Boehringer Ingelheim, Germany), in patients with DM2.Materials and methods. The study included 102 patients with DM2 (58 of them were women); the observation time was 24 weeks. The mean age was 58.3 ± 10.4 years.Results. Patients without cognitive impairment had a lower level of glycated hemoglobin (HbA1c) (7.76%, 6.18–9.34) than patients with mild dementia (8.51%, 7.02–10; p = 0.032). In the group of patients who noted the impossibility of purchasing even a part of the drugs, the level of HbA1c was 9.73% (8.95–10.51), while patients who had no difficulties in purchasing drugs HbA1c was 8.83% (7.85–9.81; p = 0.036). Empagliflozin was discontinued in 38.2% of patients for the following reasons: cost of the drug (16.6%), development of side effects (10.7%), lack of effectiveness (7.8%), other reasons (2.9%).Conclusion. Thus, the main factors influencing the adherence to treatment were the cost of the drug, development of adverse events, and lack of effectiveness from the therapy. At the same time, the opportunity of purchasing all the necessary drugs was associated with both better glycemic control and a higher quality of life. |
| format | Article |
| id | doaj-art-d03a4728c1b24b2990e2ac3564aa762b |
| institution | Kabale University |
| issn | 1682-0363 1819-3684 |
| language | English |
| publishDate | 2020-10-01 |
| publisher | Siberian State Medical University (Tomsk) |
| record_format | Article |
| series | Бюллетень сибирской медицины |
| spelling | doaj-art-d03a4728c1b24b2990e2ac3564aa762b2025-08-20T04:00:12ZengSiberian State Medical University (Tomsk)Бюллетень сибирской медицины1682-03631819-36842020-10-01193445110.20538/1682-0363-2020-3-44-511644Evaluation of factors influencing adherence to treatment with sodium-glucose cotransporter type 2 inhibitorD. A. Lebedev0A. A. Mosikian1A. Yu. Babenko2Institute of Endocrinology, Almazov National Medical Research CenterInstitute of Endocrinology, Almazov National Medical Research CenterInstitute of Endocrinology, Almazov National Medical Research CenterDespite the emergence of new groups of drugs for the treatment of type 2 diabetes mellitus (DM2), the issue of optimal adherence to treatment remains of interest.The aim of this study was to investigate the factors that influence the adherence to treatment with sodium glucose co-transporter type 2 inhibitor, empagliflozin (Jardiance, Boehringer Ingelheim, Germany), in patients with DM2.Materials and methods. The study included 102 patients with DM2 (58 of them were women); the observation time was 24 weeks. The mean age was 58.3 ± 10.4 years.Results. Patients without cognitive impairment had a lower level of glycated hemoglobin (HbA1c) (7.76%, 6.18–9.34) than patients with mild dementia (8.51%, 7.02–10; p = 0.032). In the group of patients who noted the impossibility of purchasing even a part of the drugs, the level of HbA1c was 9.73% (8.95–10.51), while patients who had no difficulties in purchasing drugs HbA1c was 8.83% (7.85–9.81; p = 0.036). Empagliflozin was discontinued in 38.2% of patients for the following reasons: cost of the drug (16.6%), development of side effects (10.7%), lack of effectiveness (7.8%), other reasons (2.9%).Conclusion. Thus, the main factors influencing the adherence to treatment were the cost of the drug, development of adverse events, and lack of effectiveness from the therapy. At the same time, the opportunity of purchasing all the necessary drugs was associated with both better glycemic control and a higher quality of life.https://bulletin.ssmu.ru/jour/article/view/2978diabetes mellitusadherence to treatmentsodium glucose co-transporter type 2 inhibitorempagliflozin |
| spellingShingle | D. A. Lebedev A. A. Mosikian A. Yu. Babenko Evaluation of factors influencing adherence to treatment with sodium-glucose cotransporter type 2 inhibitor Бюллетень сибирской медицины diabetes mellitus adherence to treatment sodium glucose co-transporter type 2 inhibitor empagliflozin |
| title | Evaluation of factors influencing adherence to treatment with sodium-glucose cotransporter type 2 inhibitor |
| title_full | Evaluation of factors influencing adherence to treatment with sodium-glucose cotransporter type 2 inhibitor |
| title_fullStr | Evaluation of factors influencing adherence to treatment with sodium-glucose cotransporter type 2 inhibitor |
| title_full_unstemmed | Evaluation of factors influencing adherence to treatment with sodium-glucose cotransporter type 2 inhibitor |
| title_short | Evaluation of factors influencing adherence to treatment with sodium-glucose cotransporter type 2 inhibitor |
| title_sort | evaluation of factors influencing adherence to treatment with sodium glucose cotransporter type 2 inhibitor |
| topic | diabetes mellitus adherence to treatment sodium glucose co-transporter type 2 inhibitor empagliflozin |
| url | https://bulletin.ssmu.ru/jour/article/view/2978 |
| work_keys_str_mv | AT dalebedev evaluationoffactorsinfluencingadherencetotreatmentwithsodiumglucosecotransportertype2inhibitor AT aamosikian evaluationoffactorsinfluencingadherencetotreatmentwithsodiumglucosecotransportertype2inhibitor AT ayubabenko evaluationoffactorsinfluencingadherencetotreatmentwithsodiumglucosecotransportertype2inhibitor |